KOD stock forecast, quote, news & analysis
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines... Show more
Why Kodiak Sciences (KOD) Stock Is Up +155.8% in the Last 30 Days
Key Takeaways
- KOD shares climbed roughly +155.8% over 30 days, from about $37.06 on September 1, 2026 to $94.80 on September 30, 2026.
- The surge followed positive Phase 3 DAYBREAK trial results announced September 28, 2026, showing Zenkuda and tabirafusp-ted met their primary endpoints in wet age-related macular degeneration (wet AMD).
- Kodiak plans to submit a Biologics License Application (BLA) for Zenkuda in the fourth quarter of 2026.
- The company remains pre-revenue and loss-making, with roughly $169.5 million in cash reported to support operations into 2027.
Kodiak Sciences (KOD) Company Overview and Market Position
Kodiak Sciences Inc. is a clinical-stage biotechnology company based in Palo Alto, California, focused on developing treatments for high-prevalence retinal diseases. Its core technology is the proprietary Antibody Biopolymer Conjugate (ABC) platform, which is designed to extend the durability and efficacy of biologic therapies delivered to the eye.
The company's lead candidate is Zenkuda (tarcocimab tedromer), an anti-VEGF therapy being developed for diabetic retinopathy, retinal vein occlusion, and wet AMD. Its pipeline also includes tabirafusp-ted (KSI-501), a bispecific IL-6 and VEGF-trap candidate, and KSI-101, a bispecific protein for macular edema secondary to inflammation. Investors follow KOD closely because the retinal drug market is large and commercially attractive, yet Kodiak has not yet generated product revenue, making its clinical and regulatory milestones the primary drivers of valuation.
Kodiak Sciences (KOD) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, KOD advanced from a closing price of $37.06 on September 1, 2026 to $94.80 on September 30, 2026, a gain of approximately +155.8%. The move was concentrated almost entirely in the final trading days of the period, when the stock spiked roughly 178% on September 28 following the DAYBREAK data release and reached a 52-week high of $95.77.
The quarterly picture tells a similar but more nuanced story. At the start of July 2026, KOD traded near $37, and for much of the quarter it drifted within a range between roughly $32 and $41 before sliding toward the low $32 area in late September. The stock closed the quarter at $94.80, representing a gain of about +154.6% from its early-July level, with essentially all of that advance occurring after the late-September clinical announcement.
What Drove KOD Stock Price in the Last 30 Days
The primary catalyst was Kodiak's announcement on September 28, 2026 that both Zenkuda and tabirafusp-ted achieved their primary endpoints in the Phase 3 DAYBREAK study in wet AMD. The trial demonstrated non-inferiority in vision gains compared with aflibercept (Eylea), and data indicated that 54% of Zenkuda-treated patients maintained vision gains through six months under a treat-to-dry retreatment criterion, highlighting the therapy's potential for extended durability.
Management described the results as validating the ABC platform's goal of rapid disease control with the potential for six-month dosing intervals. Based on the data, the company said it intends to submit a BLA for Zenkuda in the fourth quarter of 2026. The announcement triggered an unusually high trading volume of nearly 19.5 million shares and pushed the stock to a new 52-week high, as investors priced in a potential first commercial product and a path toward competing in the wet AMD market long dominated by Regeneron Pharmaceuticals (REGN) and its Eylea franchise.
What Drove KOD Stock Performance Over the Last Quarter
The broader multi-month trend was shaped by anticipation of late-stage clinical readouts. Earlier in 2026, positive Phase 3 GLOW2 results in diabetic retinopathy re-established confidence in Zenkuda after prior setbacks, and the company guided toward a September 2026 readout for the DAYBREAK wet AMD study. Institutional positioning also reflected optimism: according to SEC filings, Boxer Capital increased its KOD stake during the first quarter of 2026.
Financially, Kodiak reported a quarterly net loss of approximately $58.2 million while ending the period with about $169.5 million in cash, with management indicating resources should fund operations into 2027. The stock's quarterly gain, therefore, was driven less by sustained operational momentum and more by the successful resolution of a major binary clinical event that shifted the company's narrative from clinical-stage uncertainty toward regulatory filing and potential commercialization.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots designed to help traders monitor market opportunities across a wide range of assets. Tickeron provides hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most relevant bots are featured in this section. The bots vary in trading strategy, timeframe, and performance metrics, giving users a way to compare different automated approaches. For traders following volatile names such as KOD, these tools can provide an additional layer of quantitative analysis. Explore the Trending AI Robots page to review the available bots and their performance.
KOD Stock Forecast Drivers: What Investors Should Watch Next
Several milestones will shape KOD's trajectory. The most immediate is the planned BLA submission for Zenkuda in the fourth quarter of 2026, followed by FDA review and potential approval decisions. Investors should also monitor the Phase 3 PEAK study of KSI-101, with topline results expected in the fourth quarter of 2026, and the PINNACLE study, with data anticipated in the second quarter of 2027.
Key risks include execution on commercialization, competition from established anti-VEGF therapies, the company's lack of product revenue, and the possibility of future capital raises that could dilute shareholders. As a pre-commercial biotech, Kodiak's valuation remains highly sensitive to clinical outcomes, regulatory decisions, and financing activity. Investors should review company filings and consult their own research before making decisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
KOD in upward trend: 10-day moving average broke above 50-day moving average on September 29, 2026
The 10-day moving average for KOD crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 28, 2026. You may want to consider a long position or call options on KOD as a result. In 48 of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for KOD just turned positive on September 24, 2026. Looking at past instances where KOD's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
KOD moved above its 50-day moving average on September 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where KOD advanced for three days, in 235 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KOD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
KOD broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KOD entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. KOD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (92.593) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KOD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel therapies for the treatment of retinal disease
Industry Biotechnology